Illumina Lowers Q2 Revenue Expectations Despite Growth in Sequencing Business

Illumina said that pending stimulus grant applications caused customers to hold off on new orders during the quarter, particularly for new sequencers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.